Skip to content
NV / peptide guide
Chapter index
  1. Start
  2. Route map
  3. Meaning
  4. Questions
  5. Three paths
  6. Care route
  7. Telehealth
  8. Licenses
  9. Pharmacy
  10. Compounding
  11. Cost
  12. Coverage
  13. Evidence
  14. Sources
  15. Product checks
  16. Red flags
  17. Visit prep
  18. Label
  19. Problems
  20. Glossary

The main fork

Three paths share one search phrase

The government checks them in very different ways, and the law treats them differently. Sort the path before weighing any promise attached to it.

Map a care route

Path one: an approved medicine

  1. There is an FDA record

    As of September 2026, semaglutide (Ozempic, Wegovy) is among the peptide medicines with FDA approval.

  2. The form matters

    Use the exact generic name and form when checking the approval record or label.

Path two: a compounded preparation

  1. It is made rather than mass produced

    Compounding means a pharmacist, a doctor, or a larger FDA-registered plant (called an outsourcing facility) prepares a medicine to order instead of supplying a finished FDA-approved product.

  2. It has no FDA approval

    FDA does not verify the safety, effectiveness, or quality of a compounded medicine before it reaches the market.

  3. It still has rules

    As of September 2026, federal law says a compounder may not make what is essentially a copy of a medicine you can already buy. The exception is when your prescriber decides a change from the store-bought version matters for you personally.

Path three: a research-use sale

  1. The disclaimer does not settle it

    As of September 2026, FDA has told peptide sellers that a research-use label does not erase evidence that a product is being marketed for human use.

  2. This is not a care route

    A research chemical meant for injection is not a legal treatment route.